Adventrx Reports Positive Results of CoFactor in Metastatic Colorectal Cancer

Adventrx Pharmaceuticals has announced a 63 percent overall clinical benefit and a 38 percent objective response rate in measurable patients treated with CoFactor and 5-fluorouracil (5-FU) as a first-line treatment of metastatic colorectal cancer in its Phase II trial.

Furthermore, patients enrolled in this trial have exhibited no Grade 3 or 4 gastrointestinal or hematological toxicities as determined in accordance with the National Cancer Institute's Common Terminology Criteria for Adverse Events grading system.

Patients continue to be followed for time-to-tumor progression and overall survival. Of the 50 patients enrolled in the trial, 48 are available for tumor response assessment and 44 have been evaluated for tumor response as of May 13.